Inflammatory breast cancer in 210�patients: A retrospective study on epidemiological, anatomo‑clinical features and therapeutic results

Archive ouverte

Manai, Maroua | Finetti, Pascal | Mejri, Nesrine | Athimni, Salma | Birnbaum, Daniel | Bertucci, François | Rahal, Khaled | Gamoudi, Amor | Chaffanet, Max | Manai, Mohamed | Boussen, Hamouda

Edité par CCSD ; Spandidos Publications -

International audience. To report epidemiological and anatomo-clinical features within a retrospective series of inflammatory breast cancer and to evaluate prognostic factors. This retrospective study included 210 Tunisian patients presenting a clinically diagnosed IBC, treated at the Institute Salah Azaiez (ISA) of Tunis, Tunisia, from 2008 to 2013. We collected data on epidemiology, anatomo-clinical and biological features and histologic response to neoadjuvant therapy. Overall and disease-free survivals were calculated by Kaplan-Meier method and compared by log-rank tests and Cox's models were used to identify prognostic factors impacting survival. The 210 IBC patients had a median age of 42 years (24-62) and 15% of them were aged less than 35 years. Mean age at menarche was 13 years and 45% had their 1st childbirth before 23 years. On histology, grades III represented 42% of cases, hormone receptors were negative in 59%, HER2 over-expressed in 32, 25% of our IBC cases had a triple negative profile and Ki-67 was >20% in 53% of cases. High pathological grade III was significantly correlated to TN subtype (58%) (Fisher's exact test, P=7.5×10-3). Further, high Ki-67 expression (>20%) was evident in the TN subtype (84%) (Fisher's exact test, P=3.7×10-4). After neoadjuvant therapy (and trastuzumab in 88 and 69% of HER2+ patients, respectively), we observed 49% of objective clinical responses and 35% of pathological complete response (pCR) and >3 axillary lymph nodes were invaded on a resected tumor in 55% of cases. Overall survival (OS) was associated with age at menarche (Wald-test, P=2.2×10-2) and metastases at diagnosis (Wald-test, P=2.4×10-2). Reaching a pCR was correlated with a better metastasis-free survival (MFS), (Fisher's exact test, P=3.6×10-2).

Consulter en ligne

Suggestions

Du même auteur

MARCKS protein overexpression in inflammatory breast cancer

Archive ouverte | Manai, Maroua | CCSD

International audience. Background: Inflammatory breast cancer (IBC) is the most aggressive form of locally-advanced breast cancer. Identification of new therapeutic targets is crucial. We previously reported MARCKS...

MARCKS as a Potential Therapeutic Target in Inflammatory Breast Cancer

Archive ouverte | Manai, Maroua | CCSD

International audience. Inflammatory breast cancer (IBC) is the most pro-metastatic form of breast cancer (BC). We previously demonstrated that protein overexpression of Myristoylated Alanine-Rich C Kinase Substrate...

MARCKS protein overexpression is associated with poor prognosis in male breast cancer

Archive ouverte | Manai, Maroua | CCSD

International audience. Male breast cancer (MBC) is a rare and aggressive disease. Thus, identification of new therapeutic targets is crucial.

Chargement des enrichissements...